Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Conditions
Pancreatic Cancer · PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · Resectable Pancreatic Ductal Adenocarcinoma (PDAC) · Resected Pancreatic Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of California, Los Angeles, Los Angeles, California, United States
University of California, San Francisco, San Francisco, California, United States
Hartford Healthcare, Hartford, Connecticut, United States
Community Health Network, Indianapolis, Indiana, United States
University of Kansas Medical Center Research Institute, Inc., Lawrence, Kansas, United States
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, Maryland, United States
Saint Luke's Cancer Institute, Kansas City, Missouri, United States
Columbia University Medical Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Taylor Cancer Research Center, Maumee, Ohio, United States
Avera Cancer Institute, Sioux Falls, South Dakota, United States
University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
Virginia Cancer Specialists, Fairfax, Virginia, United States
Pan American Oncology Trials, LLC, San Juan, Puerto Rico, Puerto Rico
University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Medical Centre, Birmingham, United Kingdom
The Royal Marsden NHS Foundation Trust, Royal Marsden Hospital-London, London, United Kingdom
Imperial College Healthcare NHS Foundation Trust, Hammersmith Hospital, London, United Kingdom